TY - JOUR
T1 - Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia
AU - Treon, Steven P.
AU - Gertz, Morie A.
AU - Dimopoulos, Meletios
AU - Anagnostopoulos, Athanasios
AU - Blade, Joan
AU - Branagan, Andrew R.
AU - Garcia-Sanz, Ramon
AU - Johnson, Stephen
AU - Kimby, Eva
AU - LeBlond, Veronique
AU - Fermand, Jean Paul
AU - Maloney, David G.
AU - Merlini, Giampaolo
AU - Morel, Pierre
AU - Morra, Enrica
AU - Nichols, Gwen
AU - Ocio, Enrique M.
AU - Owen, Roger
AU - Stone, Marvin J.
PY - 2006/5/1
Y1 - 2006/5/1
N2 - Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.
AB - Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed.
UR - http://www.scopus.com/inward/record.url?scp=33646433941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646433941&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-02-0833
DO - 10.1182/blood-2005-02-0833
M3 - Review article
C2 - 16410453
AN - SCOPUS:33646433941
SN - 0006-4971
VL - 107
SP - 3442
EP - 3446
JO - Blood
JF - Blood
IS - 9
ER -